Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Mr. Brian K. Kaspar Ph.D.

Chief Scientific Officer

Mr. Michael Alexander Smith J.D.

Chief Legal Officer & Corporate Secretary

Ms. Sara M. Bonstein M.B.A.

Chief Financial Officer

Eleanor  Barisser

Associate Director of Investor Relations

Ms. S. Nicole Schaeffer M.B.A.

Chief People Strategy Officer

Mr. John Drayton Wise M.B.A.

Chief Commercial Officer

Dr. Martina  Flammer M.B.A., M.D.

Chief Medical Officer

Mandy  Fahey

Executive Director of Corporate Communications

Mr. William H. Lewis J.D., M.B.A.

President, Chief Executive Officer & Chairman

Mr. Roger  Adsett M.B.A.

Chief Operating Officer

Biotechnologijos

Insmed Incorporated

Insmed Incorporated Valdymo struktūra

Informacija apie vadovybę